Radiation experts unite to streamline cancer clinical trials

The new system has been drawn up by leading experts from across the medical physics and clinical radiology communities. It provides a standardised way of assuring that exposure to ionising radiation during clinical trials remains within safe limits, while also cutting down dramatically on duplication of work.

All new trials involving exposure to ionising radiation across the ECMC network will now use the new system, as part of a collaboration with the Health Research Authority (HRA) to begin rolling out HRA Approval, the new single approval system for health research in the NHS in England.

Giles Morrison, head of radiology physics at Sheffield Teaching Hospitals NHS Foundation Trust, who was involved in the consultation process, said: "It's wonderful to see the medical physics and clinical radiology communities working together to improve the way in which radiation exposure reviews are carried out within clinical trials.

"This will mean patients getting new treatments sooner. We're still working on the detail and I hope all ionising radiation experts will give their views to ensure that the process is the best it can be."

Greg Trevelyan, head of the UK Study Start Up Group at Roche, who are sponsoring an immunotherapy trial in patients with triple negative breast cancer, one of the first ECMC trials to undergo the new system, said: "Roche embraces initiatives that have a commitment to deliver early treatment access, whilst maintaining patient safety. As the leading pharmaceutical investor in R&D, Roche is dedicated to working with our industry colleagues in streamlining how clinical trials are set up and conducted in the UK. Above all, this new standardised system will mean any radiology issues are picked up early and provide sponsors with a single point of contact for resolution. We are delighted to be working with Cancer Research UK and the UK health departments on this initiative."

The ECMC network is also working with the HRA to pioneer a new system that allows a single designated pharmacist to review the pharmacy requirements of a clinical trial, rather than conducting multiple independent reviews at each participating hospital.

Both schemes will form part of the new HRA Approval process, which will be implemented in stages, by study type, during the course of 2015, streamlining the approvals process for research taking place within the NHS.

Professor Peter Johnson, Cancer Research UK's chief clinician, said: "We're delighted that our Experimental Cancer Medicine Centres network has been able to support this important initiative to streamline the regulation of clinical research, so patients can continue to reap the benefits from the world-class research taking place throughout the UK."